- Home
- FMBH vs MLTX Comparison
FMBH vs MLTX Comparison
Compare FMBH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMBH | MLTX |
|---|---|---|
| Founded | 1865 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FMBH | MLTX |
|---|---|---|
| Price | $51.00 | $12.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $58.29 | $30.29 |
| AVG Volume (30 Days) | 128.8K | ★ 1.6M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ 16.06 | N/A |
| EPS | ★ 3.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.46 | N/A |
| Revenue Next Year | $15.18 | N/A |
| P/E Ratio | $15.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.44 | $9.46 |
| 52 Week High | $53.36 | $23.29 |
Technical Indicators
Market Signals| Indicator | FMBH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 58.35 |
| Support Level | $50.49 | $11.88 |
| Resistance Level | $51.58 | $13.51 |
| Average True Range (ATR) | 1.13 | 0.81 |
| MACD | 0.02 | 0.25 |
| Stochastic Oscillator | 33.75 | 72.33 |
Price Performance
Historical ComparisonAbout FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.